Tag: LXX.CN

CBDNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH Platform Boosts CBD Absorption Levels

Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) innovative DehydraTECH(TM) delivery platform is patented for all nonpsychoactive cannabinoids as well as for tetrahydrocannabinol (THC) and psychoactive cannabinoids. An article discussing the company reads, “Medical researchers have struggled to find ways to penetrate the blood brain barrier effectively to transport beneficial drugs for many years. This barrier exists to block toxic or otherwise dangerous substances from entering the brain and is formed by layers of microvascular endothelial cells inside blood vessels. Lexaria’s DehydraTECH(TM) drug delivery platform brings beneficial drugs to the brain faster. . . . In June 2019, Lexaria completed a series of animal studies using an enhanced formulation of its DehydraTECH technology. This series built on the company’s original, independent, third-party laboratory in vitro lab experiments began in 2015, which showed utilization of the DehydraTECH drug-delivery platform increased the absorption levels of cannabidiol (CBD) in human intestinal cells by an impressive 499%. The results of the studies showed delivery of 1,937% more CBD into animal brain tissue after eight hours using the enhanced DehydraTECH technology in comparison with generic industry MCT coconut-oil formulations. Moreover, the animal studies using the enhanced formulation showed an 811% increase of CBD delivery into the blood in comparison with generic MCT coconut-oil formulations.”

To view the full article, visit http://cnw.fm/84SZu

About Lexaria Bioscience Corp.

Lexaria Bioscience is a global innovator in drug-delivery platforms. The company’s patented DehydraTECH drug-delivery technology changes the way active pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bioabsorption, reduces time of onset and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products, as well as to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed, in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXRP

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) CEO Posts Strategic Company Update

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, on Thursday provided a strategic update from the company’s CEO Chris Bunka. Among other highlights, the update includes a brief recap of achievements from 2019 and an outlook for the new year. “One objective for the company during 2020 is to dramatically alter our capital markets strategy. During the last six months Lexaria has met with a number of Wall Street investment banking firms as we devise our long-term capital markets strategy. Lexaria expects to pursue a strategy during 2020 to qualify for listing on a nationally-recognized US exchange, allowing a dramatically larger audience of investors to consider Lexaria’s attributes and opening a path to increased quantity and quality of strategic opportunities,” Lexaria Bioscience CEO Chris Bunka stated in the update.

To view the full press release, visit http://cnw.fm/ONk7H

About Lexaria Bioscience Corp.

Lexaria Bioscience is a global innovator in drug-delivery platforms. The company’s patented DehydraTECH drug-delivery technology changes the way active pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bioabsorption, reduces time of onset and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products, as well as to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed, in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXX

About CanadianCannabisWire

CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
www.CanadianCannabisWire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com

420 with CNW – Kansas Governor Expresses Her Support for Marijuana Legalization

On Thursday, the Governor of Kansas, Laura Kelly, said that if the state lawmakers sent a bill seeking to legalize marijuana to her desk, there is a possibility that she would sign it into law.

Speaking about the legislative priorities for 2020 in several interviews, Gov. Kelly said that the lawmakers should legalize medical marijuana as it would help Kansas families whose children are suffering from serious ailments. Medical marijuana would also help in fighting the opioid crisis by reducing the use of prescription pain medication.

Although Gov. Kelly said that she is not in favor of legalizing adult-use marijuana, she also noted that if the legislation were to advance in the state, she would enact it.

Speaking to WIBW, Kelly said that she has not made a decision on what she would do, but her decision would rely on the wants of her people; if the residents of Kansas want it, and the legislature approves it, then she would most likely sign it.

The governor further stressed that her agenda for the 2020 legislative sessions is the legalization of marijuana for medical purposes.

Kelly further said that she wants medical marijuana to be well regulated and controlled so that it does not become the gateway for the legalization of marijuana. She also said that her wish is for medical marijuana to be viewed as a pharmaceutical and controlled product.

She added and said that medical marijuana should be legalized and because of its medicinal potential, families with kids suffering from Dravet syndrome could use it. Children with Dravet syndrome experience severe and frequent epileptic seizures, which could be managed using medical cannabis.

Gov. Kelly has been outspoken about her support for medical marijuana, as it was also part of her 2018 election campaign; however, it is essential to note that she is not at all enthusiastic about recreational marijuana legalization. Kelly said that she does not think the state of Kansas is ready for adult-use marijuana, but a recent survey shows that the majority of Kansas residents are in favor of the marijuana reform.

The survey, which was released in December 2019, showed that 63 percent of the state’s residents are in support of recreational marijuana legalization. This indicates that the task remains on the legislature to approve the legislation and forward it to the Governor’s desk.

The likelihood of legalizing medical marijuana in Kansas is looking up. Last year, a special legislative commission issued recommendations in support of developing a limited medical cannabis program. The program would give patients a chance to access medical marijuana products that are neither smoked nor vaped. The commission also recommended providing patients visiting from out of state with some form of legal protection.

In an interview with KSNT, Gov. Kelly said that she is aware that people have a desire for medical marijuana legalization and that she fully supports it and hopes that the legislature would approve it.

The marijuana industry, including Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) and SinglePoint Inc. (OTCQB: SING), is most likely glad that things are looking up for the future of the industry in Kansas.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW – It’s Official, South Dakota Will Vote on Medical Marijuana Measure in 2020

For a long time, cannabis was classified with hard drugs like cocaine and heroin, a move that tarnished the plant’s image for decades. It prevented proper research into the plant and most of all kept it away from people who actually needed it. As we know, cannabis has plenty of medical properties that make it an extremely potent and versatile natural alternative to pharmaceuticals.

Before the 2018 Farm Bill legalized hemp and made it possible to sell hemp extract cannabidiol (CBD), there was medical marijuana. It led the charge as far as overhauling marijuana’s image was concerned, and on top of that, helped tons of people recuperate from a variety of medical conditions.

States like Illinois, Delaware, and California already have medical marijuana programs in place, and it seems like South Dakota may join the list. The Secretary of State’s office confirmed that a statutory measure to legalize medical marijuana in South Dakota qualified for the state’s 2020 ballot.

The proposal, now officially referred to as Initiated Measure 26, was facilitated by activists who collected more than 30,000 signatures for the petition last month. “Our office conducted a random sample of the petition signatures and found 74.65 percent to be valid,” says South Dakota Secretary of State Steve Barnett.

The reform is the first cannabis reform citizen initiative that’s made it into the ballot. A few other states have such reforms in the works, including Mississippi and Nebraska.

Aside from the medical marijuana measure, there’s a second measure to legalize adult-use marijuana that the organizers hope will reach the signature threshold in time for next year’s vote. Both of the measures are backed by national advocacy groups Marijuana Policy Project (MPP), and New Approach PAC.

“Across the country, voters are recognizing that it makes no sense to waste law enforcement resources on arresting adults for marijuana possession and that it also makes no sense to force marijuana sales into an unregulated illicit market.

Simply put, legalizing, regulating and taxing marijuana is the public policy decision that best serves the interests of public health and public safety,” says MPP Deputy Director Matthew Schweich.

“Next year, voters will have the opportunity to approve a ballot initiative that would provide legal, safe, and regulated access to medical marijuana for qualifying patients.”

Schweich argues that right now, the state government is forcing otherwise law-abiding people to be criminals in order to live healthier, happier and more productive lives. “We’re going to end that heartless injustice.”

He hopes that the adult-use legalization initiative will also qualify for the 2020 ballot. “We expect that it will, and South Dakota will be the first state in American history to vote on medical marijuana and adult-use legalization initiatives on the same ballot.”

One can only imagine what marijuana companies, such as Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) and Dama Financial, think about the odds of these ballot initiatives during the 2020 polls.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Drug-Delivery Platform Continues Reaching New Milestones

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, recently announced further advances in its proprietary, oral, drug-delivery platform: DehydraTECH(TM). An article discussing the company reads, “Lexaria’s early pilot-stage human trials with tetrahydrocannabinol (THC) delivery show its newest formulation of DehydraTECH-enhanced edibles begin providing cannabinoid effectiveness in less than 10 minutes, which is about twice as fast as traditional DehydraTECH and four to six times faster than generic industry formulations, according to a company news release (http://ibn.fm/mwAS9). . . . Lexaria has been developing DehydraTECH solutions as alternatives to smoked or vaped drug delivery over the course of the past three years, establishing a means whereby edible consumption of certain substances can provide results at rates comparable to inhaled substances and faster than ingested substances in general.”

To view the full article, visit http://cnw.fm/0iyEX

About Lexaria Bioscience Corp.

Lexaria Bioscience is a global innovator in drug-delivery platforms. The company’s patented DehydraTECH drug-delivery technology changes the way active pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bioabsorption, reduces time of onset and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products, as well as to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed, in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXX

About CanadianCannabisWire

CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
www.CanadianCannabisWire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com

420 with CNW – Democrats in Congress Cede to Senate’s Position on Veteran-Related Marijuana Provisions

Democrats in Congress have abandoned two marijuana proposals that were veteran-based and previously approved by Congress as part of their large-scale defense bill.

The House approved its version of the National Defense Authorization Act (NDAA) this summer. The legislation had several changes that would prevent the United States Department of Veteran Affairs from denying the veterans’ home loans applications due to their employment status in the legal marijuana sector.

The bill had another policy that would have allowed the military branches to reenlist service members convicted of single simple marijuana offenses.

However, the Senate did not have similar proposals in their legislation, but the leaders from the two bodies agreed to scrap some of the additional policies during the negotiations.

The Democrats did not cede on all the amendments that were not similar to the House legislation; but, both parties made compromises on the amendment proposals where the House withdrew about 630 provisions while the Senate ceded approximately 600.

The House conference negotiators did not view the marijuana measure as a priority. However, according to the sponsors of the bill, marijuana policies were to be prioritized as they represented urgent needs for the veterans and service members.

The home loan amendment provisions were made by Rep. Katherine Clark (D-MA). In May, Clark circulated a sign-on letter addressed to Veteran Affairs. The letter raised the issue and noted that a veteran in her district was denied home loan benefits because he was working in the marijuana industry.

The reenlistment waiver proposal was sponsored by Rep. Ruben Gallego (D-AZ). During a committee hearing in June, Gallego stressed that the country needs to think about military enlistment policies regarding marijuana felonies, especially looking at the recruitment crisis.

Gallego further said that the country’s views on marijuana consumption are changing, and the military has adjusted its recruitment process. He also noted that where necessary, the military can grant waivers to former simple marijuana convicts who want to serve their country.

According to a summary of the legislation, the House conference negotiators agreed on a bill funding “drug interdiction and counter-drug activities” by giving them $1 billion. The bill also calls for an assessment of the impact of any planned border wall construction would have on the quantity of narcotics entering the U.S. The bill includes the Fentanyl Sanctions Act, which puts in place several economic and financial sanctions to cease the operation of international opioid traffickers.

It is uncertain if the House Democrats will fight for the marijuana reform language in the appropriations negotiations. The current temporary spending legislation expires on December 20, and their goal is to finalize the full 2020 Fiscal Year appropriation before the expiration date.

In June, Rep. Earl Blumenauer (D-OR) withdrew a policy that would have permitted Veteran Affairs to prescribe medical marijuana to military veterans during the House consideration of the VA appending bill.

Analysts believe that cannabis industry actors, such as HTC Extraction Systems (TSX.V: HTC) (OTCQB: HTPRF) and Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), may not be too pleased that veterans will continue to be victimized for their involvement in state-legal marijuana programs.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Focuses on Pioneering New Technologies

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) is a global innovator in drug-delivery platforms focused on its patented DehydraTECH-based, drug-delivery technology and formulation development. A recent article discussing the company reads, “Earlier this year, Lexaria moved into its new head office that includes a Health Canada-licensed research and development laboratory that is being used to conduct world-leading research into drug-delivery methods and improvements. In addition to accelerating research in the company’s DehydraTECH drug-delivery platform, Lexaria is also considering issuing a limited commercial release of DehydraTECH version 2.0, which has been shown to deliver 811% more CBD into animal blood than generic industry control formulations, the company stated in an update to shareholders (http://cnw.fm/VV6qg). . . . Lexaria’s focus on pioneering new technologies that can more efficiently deliver APIs into the bloodstream, where they can have their desired effect, includes developing an effective way to cross the blood-brain-barrier. Lexaria’s DehydraTECH version 2.0 is showing promise in this arena as testing indicated 1,937% more CBD reached animal brain tissue compared to generic industry control formulations.”

To view the full article, visit http://cnw.fm/8Frfv

About Lexaria Bioscience Corp.

Lexaria Bioscience is a global innovator in drug-delivery platforms. The company’s patented DehydraTECH drug-delivery technology changes the way active pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bioabsorption, reduces time of onset and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products, as well as to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed, in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXX

About CanadianCannabisWire

CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
www.CanadianCannabisWire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Names Senior Advisor to Outline Leadership Strategies

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator with technology that has demonstrated its ability to enhance the oral delivery of nicotine, recently appointed Gregg Smith, founder of a New York-based culture-tech, venture investment firm, as senior advisor to help define LXRP’s leadership strategies. An article discussing the company reads, “‘I am passionate about creating a smokeless future and recognize that the consumption methods of nicotine and cannabis will change,’ Smith stated in the news release (http://cnw.fm/KaCZ3). ‘Lexaria’s technology, DehydraTECH(TM), will completely disrupt and improve the consumption and delivery of oral nicotine, CBD and cannabis. Lexaria’s recognition of the recent FDA recognition of certain oral delivery forms of nicotine as ‘less harmful’ to human health than combustible smoking will be a driving force of changing consumer preferences.’”

To view the full article, visit http://cnw.fm/19XOk

About Lexaria Bioscience Corp.

Lexaria Bioscience is a global innovator in drug-delivery platforms. The company’s patented DehydraTECH drug-delivery technology changes the way active pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bioabsorption, reduces time of onset and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products, as well as to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed, in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXX

About CanadianCannabisWire

CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
www.CanadianCannabisWire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com

420 with CNW – Minnesota Expands Medical Cannabis Program

On Monday, the Health Department in Minnesota announced that come 2020, residents of the state suffering from chronic pain and age-related macular degeneration would be qualified to register for the medical marijuana program.

The Health Department also approved two delivery methods to give patients the option to choose from. The two systems include water-soluble cannabinoid multi-particles such as powders, granules, and sprinkles, and orally dissolvable products such as gums, mints, lozenges, buccal pills, and sublingual tablets.

Earlier this year, the lawmakers passed a law permitting the medical marijuana manufacturers for the program to double the number of marijuana treatment centers accessible by patients. The number of centers will be eight, making medical marijuana products more accessible to patients.

One of the medical marijuana manufacturers is Leafline Labs, and they suggested treatment centers to be set up at Willmar, Mankato, Golden Valley, and Rogers. Minnesota Medical Solution is the other manufacturing company, and it has proposed centers to be located at Woodbury, Blaine, Duluth, and Burnsville.

The Health Commissioner in Minnesota, Jan Malcolm, said that the increase in treatment centers and delivery methods would give patients more options, especially with the potential health impact of vaping.

In a statement, Malcolm further said that she is hopeful that with the new delivery methods, patients will have an alternative way of using medical marijuana, and the treatment centers will be easily accessible. The state’s program is a bit strict as it does not allow patients to access cannabis in leaf form or consume it through smoking. And before, patients could only access weed in the form of liquid gel, topical ointment, pills, and vape products.

Malcolm also said that the department added chronic pain to the list of qualifying conditions after reviewing the positive evidence where people have been using medical pot to treat intractable pain. She also noted that the age-related macular degeneration was added to the list after the agency found no other viable options for managing the symptoms.

The policy director for Sensible Change Minnesota, Maren Schroeder, said that doctors have been slow in certifying intractable pain since it carries a particular legal definition whereby it should be pain that cannot be cured but only managed, and other treatment options have failed to relieve the symptoms.

Patients identified to be suffering from chronic pain or age-related macular degeneration qualify to register with the medical marijuana program come July 1, 2020. They will be able to access medical marijuana treatment from manufacturers in the state on August 1.

The medical marijuana program in Minnesota started in 2014, when the state’s Department of Health approved only nine qualifying conditions.

In October 2019, approximately 18,000 patients were registered with the state’s medical marijuana program. The expansion of the program is seen by analysts as a move that will address some of the concerns of the entire industry, such as IONIC Brands Corp. (CSE: IONC) (OTC: IONKF) and Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), since the expanded program allows more patients to benefit.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Set to Profit from FDA’s MRTP Pathway Announcement

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator with technology that has demonstrated its ability to enhance the oral delivery of nicotine, is positioned to benefit from the FDA’s recent announcement that it had authorized the marketing of eight smokeless tobacco products through the modified-risk, tobacco-product (“MRTP”) pathway (http://cnw.fm/PaC87). An article discussing the company reads, “The FDA approval of the ‘modified risk’ claims was made after reviewing scientific evidence submitted by the manufacturer of the products. The approvals, which are product specific and expire after five years, do not mean the products come with no health risks. Nicotine-based products are addictive and may, according to some studies, induce the onset of cardiovascular, respiratory and gastrointestinal disorders. . . . The patented DehydraTECH(TM) drug-delivery platform mitigates a serious limitation to nicotine ingestion. The human GI system struggles to process nicotine in the forms in which it is presently offered, one reason why there are currently no edible, nicotine, manufactured products available, although some natural foods — eggplant, green pepper, potato, tomato — do contain nicotine. However, DehydraTECH employs a delivery mechanism that improves the bioabsorption and bioavailability of many ingestible substances, as well as their taste and smell, by using lipophilic agents. Application of the technology extends beyond nicotine to nonpsychoactive cannabinoids, vitamins and nonsteroidal anti-inflammatory drugs (NSAIDs).”

To view the full article, visit http://cnw.fm/W5qBi

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. is a global innovator in drug-delivery platforms. Its patented DehydraTECH drug-delivery technology changes the way active pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bioabsorption, reduces time of onset and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products, as well as to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed, in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXX

About CanadianCannabisWire

CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
www.CanadianCannabisWire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com